Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

NCT03006367 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: NFC-1 100 mg
DRUG: NFC-1 200 mg
DRUG: NFC-1 400 mg
DRUG: NFC-1 800 mg

Sponsor

Aevi Genomic Medicine, LLC, a Cerecor company